GSE229973 cisplatin 4 v 2 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE229973_cisplatin_4_v_2_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE229973_cisplatin_4_v_2_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE229973_cisplatin_4_v_2_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE229973_cisplatin_4_v_2_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

H3.3 histone A

Gene

small nucleolar RNA host gene 4

Gene

GTP binding protein 6

Gene

endogenous Bornavirus like nucleoprotein 3, pseudogene

Gene

long intergenic non-protein coding RNA 3052

Gene

colorectal cancer associated 1

Gene

long intergenic non-protein coding RNA 2577

Gene

notch 2 N-terminal like R

Gene

KLRK1 antisense RNA 1

Gene

cervical cancer associated DHX9 suppressive transcript


  • Gene

    small nucleolar RNA host gene 4


  • Gene

    GTP binding protein 6


  • Gene

    endogenous Bornavirus like nucleoprotein 3, pseudogene


  • Gene

    long intergenic non-protein coding RNA 3052


  • Gene

    colorectal cancer associated 1


  • Gene

    long intergenic non-protein coding RNA 2577


  • Gene

    notch 2 N-terminal like R


  • Gene

    KLRK1 antisense RNA 1


  • Gene

    cervical cancer associated DHX9 suppressive transcript

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.